Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 2/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.44 |
| ▸ | AQP1 | P29972 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4232272 | 0.88 | AQP1 (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4232800 | 0.86 | PRKAB2 (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4233581 | 0.85 | PRKAB2 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4596816 | 0.84 | DHFR (0.40) | ALDH1A1MAPK1NPC1LMNAMAPT | |
| SCHEMBL4596811 | 0.83 | HTR7 (0.32) | HTR2CHTR7HTR2AALDH1A1MAPK1 | |
| SCHEMBL4225236 | 0.83 | AQP1 (0.62) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4221882 | 0.83 | AQP1 (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4230589 | 0.82 | PRKAB2 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4226195 | 0.81 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4224837 | 0.81 | PRKAB2 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1998764-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-10 | — | — | EP | claimed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | claimed |
| US-7396857-B2 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2008-07-08 | — | — | US | claimed |
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | claimed |
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1871355-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2007112065-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | WYETH (US) | 2007-10-04 | — | — | WO | claimed |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20060258712-A1 | Methods for modulating bladder function | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258711-A1 | Treatment of drug abuse | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | GRIN3A, GRIN2A, BDNF | PRKAB2 3384/4885PRKAG1 3443/4885PRKAA2 3940/4885 |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | TTPA, GAP43, SLC6A3 | PRKAB2 3768/4885PRKAG1 3769/4885PRKAA2 4325/4885 |
| US-20060258711-A1 | Treatment of drug abuse | OPRK1, OPRM1, ADH1A | PRKAB2 2840/4885PRKAG1 2552/4885PRKAA2 3592/4885 |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | CHAT, COMT, ACHE | PRKAB2 2928/4885PRKAG1 3153/4885PRKAA2 4581/4885 |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | HTR1F, HTR2C, HTR3D | PRKAB2 4363/4885PRKAG1 4343/4885PRKAA2 3304/4885 |
| US-20060258712-A1 | Methods for modulating bladder function | PDE3A, PDE3B, PDE2A | PRKAB2 1021/4885PRKAG1 1420/4885PRKAA2 3163/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | PRKAB2 2598/4885PRKAG1 2441/4885PRKAA2 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.